Search
Neon
go.drugbank.com/drugs/DB11589ApprovedNeon may be used in the clinical setting as a diagnostic tracer gas in a gas analyzer for a lung diffusion test. … It is the fifth most abundant chemical element in the universe by mass but a rare element on Earth.
Padimate O
go.drugbank.com/drugs/DB11570ApprovedPadimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA [L2153]. … It penetrates human skin, and is shown to induce non-ligatable strand breaks on DNA _in vitro_ and mutagenic effects on yeast i_n vivo_ [A32458].
Mixtures: Skin Pro-tec II SPF-15, Dermatone SPF 23 Lips N Face ProtectorCategories: Compounds used in a research, industrial, or household settingAltretamine
go.drugbank.com/drugs/DB00488ApprovedWithdrawnAn alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.
Biotin
go.drugbank.com/drugs/DB00121ApprovedInvestigationalNutraceuticalA water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.
Mixtures: Multi II IV Vi Tab, Vc IIProducts: BIO-H-TIN Vitamin H 5 mg - Tabletten, BIO-H-TIN Vitamin H 2,5 mg - TablettenLutetium Lu 177 dotatate
go.drugbank.com/drugs/DB13985ApprovedInvestigationalPatients with GEP-NETs have limited second-line treatment options after the metastasis of tumors and inadequate therapeutic response from first-line therapies. … In a clinical trial involving patients with advanced somatostatin receptor-positive GEP-NET, the treatment of Lutetium Lu 177 dotatate in combination with octreotide resulted in longer progression-free
Categories: Compounds used in a research, industrial, or household settingSilicon
go.drugbank.com/drugs/DB12982ApprovedSilicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or … Stage II Mycosis Fungoides).
Mixtures: Procosa II, Calcium With Mg Zn Mn Cu CR Si and Vit. C & DTisagenlecleucel
go.drugbank.com/drugs/DB13881ApprovedInvestigationalIt was granted approval by FDA in August 2017 under the market name Kymriah. … In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent
Lazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.
Synonyms: N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE, 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-Glipizide
go.drugbank.com/drugs/DB01067ApprovedInvestigationalAccording to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. … It was first introduced in 1984 [A179491] and is available in various countries including Canada and the U.S.
Categories: Drugs Used in DiabetesSynonyms: N-{4-[β-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylureaCoagulation factor X human
go.drugbank.com/drugs/DB13148ApprovedInvestigationalHowever its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe hereditary Factor X deficiency. … While Factor X normally circulates in the plasma as inactive molecules, the activation of Factor X is involved in both the intrinsic and extrinsic coagulation pathways.
Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET